Development of MCM-41 mesoporous silica nanoparticles as a platform for pramipexole delivery
-
Published:2019-06
Issue:
Volume:51
Page:26-35
-
ISSN:1773-2247
-
Container-title:Journal of Drug Delivery Science and Technology
-
language:en
-
Short-container-title:Journal of Drug Delivery Science and Technology
Author:
Tzankov Borislav,
Tzankova Virginia,
Aluani Denitsa,
Yordanov YordanORCID,
Spassova Ivanka,
Kovacheva Daniela,
Avramova Kati,
Valoti Massimo,
Yoncheva Krassimira
Subject
Pharmaceutical Science
Reference66 articles.
1. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities;Kreiss;Eur. J. Pharmacol.,1995
2. Efficacy, safety, and toleranceof the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study;Pinter;J. Neurol. Neurosurg. Psychiatry,1999
3. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease;Mizuno;Mov. Disord.,2003
4. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+) 2-amino-4, 5, 6, 7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride];Danzeisen;J. Pharmacol. Exp. Therapeut.,2006
5. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells;Kitamura;Mol. Pharmacol.,1998
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献